Dr. Reddy’s Laboratories has launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Dr. Reddy’s Hervycta is available in strengths of 150mg and 440mg multiple dose vials. Dr. Reddy’s currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.
Herceptin (marketed as Herclon in India) and its biosimilars had India sales of around Rs 290 crore MAT for the most recent twelve months ending in December 2017 according to Ipsos.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
